KALA Stock Analysis: Buy, Sell, or Hold?
KALA - KALA BIO, Inc. Common Stock
$0.82
-0.02 (-2.38%)
▼
5d:
-13.26%
30d:
+34.38%
90d:
-68.46%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When KALA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KALA is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KALA is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: KALA is currently trading at $0.82, which is considered fair relative to its 30-day fair value range of $0.69 to $0.87.
Technical Outlook: Technically, KALA is showing sideways momentum. Immediate support is located at $0.73, while resistance sits at $1.00.
Market Sentiment: KALA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.50 (+82.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KALA is showing sideways momentum. Immediate support is located at $0.73, while resistance sits at $1.00.
Market Sentiment: KALA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.50 (+82.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.69 -
$0.87
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.9% below Wall St target ($1.50)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.69 -
$0.87
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.73
Resistance Level
$1.00
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.55
Wall Street Target
$1.50
(+82.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 24, 2026 1:28 AM ET
Data refreshes hourly during market hours. Next update: 2:28 AM
Data refreshes hourly during market hours. Next update: 2:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KALA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
